Top Markets
Coin of the day
Icosavax, Inc. Icosavax, Inc.

Icosavax, Inc.

ICVX
Ранг среди акций #25854
Icosavax, Inc. operates as a biopharmaceutical firm dedicated to developing... Icosavax, Inc. operates as a biopharmaceutical firm dedicated to developing immunizations against infectious diseases. Leveraging its proprietary virus-like particle (VLP) platform technology, the company primarily focuses its efforts on severe respiratory illnesses. Its developmental portfolio includes several key vaccine candidates: IVX-121, an RSV-targeted vaccine currently undergoing Phase 1/1b clinical trials; IVX-A12, a bivalent candidate designed to target both respiratory syncytial virus (RSV) and human metapneumovirus (hMPV); IVX-241, a candidate specifically designed for hMPV; and IVX-411, a SARS-CoV-2 vaccine based on a receptor binding domain (RBD) sequence antigen, which is also in Phase 1/2 clinical trials. Established in 2017, Icosavax maintains its corporate headquarters in Seattle, Washington.
Цена акции
$15.31
Последняя синхронизация: 2024-02-29
Рыночная капитализация
$45.70M
Изменение (1 день)
0.00%
Изменение (1 год)
0.00%
Страна
US
Торговля Icosavax, Inc. (ICVX)

Категория

EPS для Icosavax, Inc. (ICVX)
EPS по состоянию на 2026 TTM: 0
Согласно последним финансовым отчетам и цене акций Icosavax, Inc., текущий EPS компании (TTM) составляет 0. В конце 2026 EPS компании составлял 0, равна показателю 2026 года, равному 0.
История EPS компании Icosavax, Inc. с 2026 по 2026
EPS на конец каждого года
Год EPS Изменить
Недостаточно данных для указанных дат.
EPS для аналогичных компаний или конкурентов
Компания EPS Разница в EPS Страна
$17.32 -
US
$27.74 -
NL
$2.98 -
AU
- -
CH
$-7.98 -
US